General
SCORPION THERAPEUTICS RECEIVES BIOSPACE NEXTGEN BIO “CLASS OF 2022” RECOGNITION
BOSTON, Mass. – January 5, 2022 – Scorpion Therapeutics, Inc. (“Scorpion”), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, has been selected by BioSpace to join its NextGen Bio “Class of 2022.” The recognition from BioSpace,
Read MoreGeneral
SCORPION THERAPEUTICS REVEALS HIGHLY-SELECTIVE LEAD PROGRAMS TARGETING MUTANT PI3Kα AND EGFR EXON 20, TWO ESTABLISHED CANCER DRIVERS WITH BROAD THERAPEUTIC APPLICABILITY
— Rapid discovery of lead compounds driven by Scorpion’s Precision Oncology 2.0 strategy, and enabled by its fully integrated drug-hunting platform — — Both mutant PI3Kα and EGFR Exon 20 programs are potentially best-in-class, exquisitely selective small molecule compounds — — Investigational new
Read MoreGeneral
SCORPION THERAPEUTICS ANNOUNCES APPOINTMENT OF BRIAN PIPER AS CHIEF FINANCIAL OFFICER
BOSTON, Mass. – November 22, 2021 – Scorpion Therapeutics, Inc. (“Scorpion”), a next-generation oncology company whose goal is to develop best- and first-in-class precision medicines for people with cancer, today announced the appointment of Brian Piper as the company’s first Chief Financial
Read More